Is Lenmeldy (atidarsagene autotemcel) expensive? Where can I buy it?

Lenmeldy (atidarsagene autotemcel) is a cutting-edge gene therapy for a rare genetic disease called metachromatic leukodystrophy (MLD). MLD is caused by biallelic mutations in the arylsulfatase A (ARSA) gene, which results in reduced ARSA enzyme activity, thereby affecting the normal development and function of the brain and nervous system. Lenmeldy is particularly suitable for two types of pediatric patients: one is patients with late infantile or early adolescent MLD who have no clinical manifestations; the other is patients with early adolescent MLD who have early clinical manifestations but are still able to walk independently and have not yet experienced cognitive decline.

In the United States,Lenmeldy has been approved to treat these children with presymptomatic or early symptomatic MLD. It uses a one-time, individualized single-dose infusion, using the patient's own hematopoietic stem cells for genetic modification. Specifically, stem cells collected from the patient are added with a functional copy of the ARSA gene, and then these modified stem cells are transplanted back into the patient, where they implant and multiply in the bone marrow. These engineered stem cells are able to produce the ARSA enzyme, which is critical for breaking down harmful sulfatides that accumulate in the body, potentially halting the progression of MLD.

However, before receivingLenmeldy treatment, patients must undergo high-dose chemotherapy to clear the original cells in the bone marrow to make room for the modified stem cells. Although this process increases the complexity of treatment, it is also an indispensable step to ensure the effectiveness of treatment. The emergence of Lenmeldy has brought new hope to MLD patients. Although the treatment process is complicated and expensive, it is undoubtedly a treatment worth looking forward to for those children who are eager to defeat the disease and regain health.

Lenmeldy is a new treatment approved by the US FDA last year. It is very expensive and this treatment has not yet been carried out in China. If patients have needs, it is recommended to consult a regular overseas medical consulting company for detailed information.

Reference link:https://www.drugs.com/lenmeldy.html